PERHAPS it is best to introduce this discussion with a few general statements to clarify the position which we have maintained throughout the past years. We have held that anticoagulant therapy for myocardial infarction does not constitute tlhe ultimate, the comprehensive, or even an entirely satisfactory form of therapy for this condition. If research directed at the prevention or reversal of atherosclerosis is crowned with success, the need for anticoagulant therapy will be decreased proportionately. Meanwhile, however, efforts to minimize the thrombotic tendency in the chambers and the progressively narrowing arteries of the heart and other organs, and also in the venous systems seems a logical and effective method of approach.
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Second, we have urged the pursuit of excellence. We do not consider that either inadequate or excessive use of these drugs is defensible, or that conclusions regarding their value can justifiably be drawn from such experiences. The disappointing and occasional tragic effects of their use have too often been an index of the percentage of time the patients have not been at optimal therapeutic levels as well as the lack of training or conscientiousness of the responsible clinician, laboratory technician, or the patient, rather than the drug itself. Untoward September 1964 pathologic states such as cancer or ulcers. Investigation into many such cases has provided adequate evidence on these points, and they need not be belabored further. The first of these problems is susceptible to correction by adequate training of technicians and of the coming generations of physicians as well as comprehensive instructions to each patient. This has been demonstrated in many hospitals and medical schools where sufficient emphasis has been given to these considerations. It is also essential that the selection of patients, for both short-and long-term therapy, be undertaken with sound judgment.
The report of the Committee on Anticoagulants of the American Heart Association which appeared in 19541 remains the most detailed and comprehensive analysis of this problem thus far produced. With the passage of time, however, the plan of organization of this study has been forgotten by some. Nineteen of America's leading cardiologists were responsible for the accumulation of the data from the various medical centers. They inWRIGHT who helped to plan the study were Dr. Lowell Ried of the Johns Hopkins University and Dr. Samuel Fertig of Columbia University, two of the most distinguished biostatisticians in this country. The details of the collection of the data and the methods of analysis are available for review in the 700-page report. The publication appeared after 8 years of detailed analysis and study. In summary, 1,031 patients were divided into control and treated groups, those receiving anticoagulants depending solely on whether they entered the hospital on odd or even days of the month.
The death rate in the control group was 23.4 per cent-in the treated group 16 per cent, a difference which was found to be statistically significant. Most of the improvement was related to the reduction in thromboembolic complications. In 20 other series reviewed at the time of the publication of the Committee Report' totaling 2,812 controls and 1,924 treated cases, the death rate was found to be reduced from 29.5 per cent to 14.8 per cent. The improvement in the death rate in the American Heart Association study was significant during the period of effective Dicumarol therapy, beginning the fourth day of treatment and through the fourth day after discontinuing treatment. With the introduction of treatment with heparin, some recent series suggest improvement even during the first few days but this is as yet not fully established. In the American Heart Association series, there was improvement in each age group and especially from 60 to 79 years. This differs from some other studies where less evidence of benefit has been found in the older patients. Both men and women showed improvement. Some other studies have reported little benefit for women but examination usually shows the figures to be too small for valid statistical treatment. Improvement was noted in all weight groups, but those 10 We now know that fibrinolysis may continue for some hours after death, which may account in some cases for the lack of finding thrombi when they might logically have been found. Other factors to be considered should include spasm of an already damaged coronary artery, and sudden drop in blood pressure as with severe hemorrhage or operation. Only 3 per cent of cases showed occlusion due to subintimal hemorrhage, although these were diligently sought for. Clinically 36 thromboembolic complications per 100 cases were found in the controls compared with 13 in the treated cases but at autopsy, 124 extracardiac thromboembolic complications were found in the control group per hundred cases compared with 42 in the treated group. The number of thromboemboli found at autopsy uniformly exceeded the number diagnosed clinically. This disposed of the criticism that the clinicians were overdiagnosing such complications. 1.9 per cent of the controls died with rupture as against 3 per cent of the treated group, a difference of 1.1 per cent; five of the eight treated cases who died of rupture died in the first 3 days when the anticoagulant effect was considered to be none or slight. The total difference in deaths from hemorrhage or rupture was 1.7 per cent, leaving a gain of 7.4 lives per one hundred cases during the first month of treatment. This does not include the reduction in secondary myocardial infarctions, multiple embolization, and venous thromboses not producing death. Many of these Circulation, Volume XXX, September 1964 were serious and showed significant reduction at valid levels.
Confirmation
In general the results reported in this study have been duplicated in more than a hundred studies carried out for the same purpose in many geographic areas. Numerous modifications in methodology have been used, but unanimity in the results has been surprisingly high.
In these confirmatory studiej the mortality rate from acute myocardial infarction has been quite uniformly reduced one third to one half, and the thromboembolic complication rate one half to three fourths. Many of these have been discussed by Douglas 2 (tables 1 and 2). True, the perfect study has not emerged-fundamentally because of the variable human factors both on the part of the investigators and the patients. There have been those who have belittled the importance of thromboembolic complications. In addition to their effect on the death rate, these complications have produced hemiplegia, pulmonary hypiertension, occlusion of major peripheral arteries (even the aortic bifurcation), and chronic venous insufficiency, When authors imply that complications such as these are unimportant, one wonders just how thoroughly they follow the life history of their patients. Most internists of experience think they are important, and constitute major reasons for reducing the thrombosing tendency of the blood in disease states in which thromboembolism poses a threat. On the opposite side of the ledger, a few studies, far smaller in number, have ended with results that fail to indicate significant value from this form of treatment, and some critics have continued to emphasize the risks of anticoagulant therapy. It cannot be assumed that because the results are not favorable, a study has necessarily been conducted in a manner that is equal or superior to Cardiac rupture with death occurred in five patients. Four of these occurred in the first 48 hours, four occurred in women, and four of the five had never received anticoagulants. These figures dealing with rupture are of interest, mainly in that they indicate that small numbers or subgroups in a series such as this can fall one way or another to give impressions that may be incorrect, but unfortunately are too often interpreted as significant and lead to erroneous conclusions. Autopsies were performed in 60 per cent of those dying. Of interest in relation to the question of the effect of anticoagulants on the incidence of rupture of the myocardium is the report of Ross and Young12 from the Western Infirmary, Glasgow. These workers reviewed 606 autopsies of patients who died from myocardial infarction. In this group there were 43 instances of rupture (7 per cent). In this study the authors found no increase in rupture in the patients who had received anticoagulants. Fischer 13 Table 7 Recurrence of Infarction (Bjerkelund) (table 9) . Lack of maintenance of the gain at significant levels after the second year may be in part explained by the accumulation of borderline cases in the treated group, whereas their counterparts have died off in the control group, leaving only those with the least damage surviving. In this manner, the longer the study is continued the more the treated group becomes biased against itself. Inevitably this should show up at the second to the fourth year. There is also the problem of patient 'fall out" mentioned above. This varies widely, depending largely on the quality of leadership provided by the physician and his staff. It has been implied t-hat, since the gain cannot always be maintained indefinitely, the treatment is of no value. This is not a valid position. Most patients will elect to take advantage of any treatment that will reduce their risk even for a year ot two. A 9-year study from the University of Chicago by Kuhn, Van Ness, Jones, and Bay17 has recently appeared. Patients were divided into three groups: 166 received long-term anticoagulant therapy for 2 years or until death; 270 served as controls; and 147 were treated for half time and served as controls for half time. The 2-year mortality for the "full treated" cases was 13 per cent as against the controls with 26 per cent. The patients who were treated only part of the 2 years had a markedly lower incidence of recurrent infarction and death while on than while off therapy. When all three groups were included in the calculations, the treated patients had a mortality rate of 5.6 per cent compared with 14.4 per cent per year in the controls, and the incidence of proven recurrent myocardial infarction in the treated group was 5.4 per cent while in the controls it was 11.1 per cent per year (table 10). 
